OmicsBank raised $2.25 million to help bring overseas patient data to biopharma, aiming to expand data availability for model training and translational research use cases. The company’s focus centers on improving access to global patient cohorts that can be used to strengthen AI and data-driven discovery pipelines. The funding highlights continued investor appetite for data infrastructure—especially when paired with patient-level information needed for drug development analytics rather than only synthetic or publicly curated datasets. For biopharma teams, additional data access can reduce bottlenecks in cross-cohort model building and validation.